Skip to main
COGT

COGT Stock Forecast & Price Target

COGT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences is positioned for success with its focus on developing precision therapies for genetically defined diseases, particularly its program CGT9486 which has shown promising results in treating diseases caused by the KIT D816V mutation. With a strong emphasis on rational precision and addressing underlying causes, this innovative company shows potential for long-term growth and value creation. However, investors should be aware of potential risks such as negative clinical results or the emergence of superior competitor products which could impact valuation.

Bears say

Cogent Biosciences is facing a negative outlook due to its ongoing net losses and high R&D and SG&A expenses, leading to a projected full-year net loss increase for 2026. The company's financials show that it has a good amount of cash on hand, but the potential for M&A could be a distraction and may not solve their financial woes. With multiple regulatory timelines and data presentations coming up, the success of their lead program bezuclastinib is still uncertain, making it a risky investment at this time.

COGT has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogent Biosciences, Inc. (COGT) Forecast

Analysts have given COGT a Buy based on their latest research and market trends.

According to 11 analysts, COGT has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogent Biosciences, Inc. (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.